Amgen EPO Medicare Claims To Be Monitored Via Dose Levels – CMS Draft

Medicare claims for use of Amgen's Aranesp and Epogen in end-stage renal disease will be monitored through blood hematocrit or hemoglobin levels as well as dosage levels, a Centers for Medicare & Medicaid Services' draft policy says